News Releases

Date Title and Summary
Toggle Summary electroCore Announces Regulatory Approval in Canada to Treat Adolescent Migraine
Health Canada expands gammaCore label to include the acute and preventive treatment of migraine in adolescents ROCKAWAY, NJ , Oct. 14, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that the company received an amended
Toggle Summary electroCore Provides Business Update and Select Third Quarter 2021 Financial Guidance
Third q uarter 2021 revenue expected to be approximately $1.5 million Net cash used to fund operations in the third quarter 2021 of approximately $3.5 million ROCKAWAY, NJ , Oct. 12, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today
Toggle Summary electroCore Announces Acceptance of Motion to Dismiss in the Federal Court Securities Class Action Suit
ROCKAWAY, NJ , Oct. 07, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced the granting of the company’s motion to dismiss the federal court securities class action case filed in Trenton, NJ .
Toggle Summary electroCore Presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference
ROCKAWAY, NJ , Sept. 30, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference has been rescheduled to today, September 30,
Toggle Summary electroCore Announces Open Access and Submission of Manuscript from SAVIOR-1 study of Non-Invasive Vagus Nerve Stimulation (nVNS) in Hospitalized COVID-19 Patients
ROCKAWAY, NJ , Sept. 29, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the original author manuscript from the SAVIOR-1 study; a prospective, randomized, controlled study evaluating non-invasive vagus nerve
Toggle Summary electroCore to Participate at Upcoming Investor Conferences
ROCKAWAY, NJ , Sept. 23, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give a corporate presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference .  The
Toggle Summary electroCore Announces Peter Cuneo as Board Chairman
ROCKAWAY, NJ , Sept. 20, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the Board of Directors has appointed Peter Cuneo as Chairman of the Board of Directors effective October 1, 2021 . Mr.
Toggle Summary electroCore Announces New Patent Expanding Claims Related to Delivery of Non-Invasive Vagus Nerve Stimulation Therapy Using Mobile Devices
ROCKAWAY, NJ , Sept. 15, 2021 (GLOBE NEWSWIRE) --   electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office has issued US Patent No. 11,097,102 to electroCore, relating to devices, systems and methods
Toggle Summary electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Paroxysmal Hemicrania and Hemicrania Continua
ROCKAWAY, NJ , Sept. 14, 2021 (GLOBE NEWSWIRE) --   electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that on September 10, 2021 the company received Section 510(k) clearance from the United States Food and Drug Administration (FDA) of the
Toggle Summary electroCore to Present at the HC Wainwright 23rd Annual Global Investment Conference
ROCKAWAY, NJ , Aug. 31, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give a corporate presentation at the HC Wainwright 23rd Annual Global Investment Conference .